The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA

Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA

December 25, 2015 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Phase 3 Trial of Ixekizumab & Adalimumab in bDMARD-Naive Patients with Active PsA
Ixekizumab is an investigational IgG4 monoclonal antibody that binds with high affinity and specificity to cytokine IL-17A. In this 24-week, double-blind, placebo-controlled, Phase 3 clinical trial, adult patients with active psoriatic arthritis (PsA) who were naive to biologic disease-modifying anti-rheumatic drugs (bDMARDs) (n=417) were randomized into four treatment groups: placebo (n=106); 40 mg adalimumab once every two weeks, which was the active control (n=101); 80 mg ixekizumab once every two weeks after receiving an initial 160 mg dose at Week 0 (n=103); or 80 mg ixekizumab once every four weeks after receiving an initial 160 mg dose at Week 0(n=107).1

You Might Also Like
  • Certolizumab Pegol Combination Therapy Better than Methotrexate Monotherapy in DMARD-Naive Patients with RA
  • Certolizumab Pegol Effective for Treating Rheumatoid Arthritis
  • Clinical Trial of Ixekizumab for Psoriatic Arthritis Shows Positive Results
Also By This Author
  • FDA Update: Romosozumab’s Uncertain Future; Plus Tocilizumab Approved for GCA

Three hundred and eighty-two patients completed the study. A significantly greater percentage of patients taking 80 mg ixekizumab once every two weeks or 80 mg ixekizumab once every four weeks achieved ACR20, ACR50, ACR70 and PASI 75/90/100 responses than placebo-treated patients at Weeks 12 and 24 (p<0.01). At Week 24 for placebo, 40 mg adalimumab once every two weeks, 80 mg ixekizumab once every two weeks and 80 mg ixekizumab once every four weeks, respectively, the ACR20 was 30%, 57%, 58% and 62%; the ACR50 was 15%, 39%, 40% and 47%; and the ACR70 was 6%, 26%, 23% and 34%. The PASI 100 response was 3% for placebo, 24% for 40 mg adalimumab once every two weeks, 43% for 80 mg ixekizumab once every two weeks and 53% for 80 mg ixekizumab once every four weeks.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Measures of dactylitis (LDI-B) showed significant reductions for both ixekizumab groups compared with placebo. At Week 24, the incidence of treatment-emergent adverse events and the rate of serious adverse events in patients were higher with adalimumab and ixekizumab compared with placebo-treated patients. Discontinuations due to adverse events were also similar across treatment groups. No deaths occurred.

Does Treatment of Severe, Progressive RA Improve Outcomes?
A Phase 3 study, known as C-EARLY, evaluated disease-modifying anti-rheumatic drug (DMARD)-naive patients with severe, active, progressive rheumatoid arthritis (RA), assessing the efficacy and safety of certolizumab pegol plus methotrexate compared with placebo plus methotrexate to induce and maintain a sustained clinical response and inhibit radiographic damage. This trial was a multicenter, double-blind, randomized study in patients with an RA diagnosis of less than one year who met the 2010 ACR/EULAR criteria and other relevant specifications.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients (n=879) were randomized 3:1 to receive certolizumab pegol (400 mg at Weeks 0, 2 and 4; and 200 mg every two weeks to Week 52) plus methotrexate or placebo plus methotrexate once every two weeks. Methotrexate was started as a 10 mg weekly dose and increased up to a 25 mg weekly dose by Week 8. Patients unable to tolerate ≥15 mg of methotrexate by Week 8 were withdrawn from the study. A greater proportion of certolizumab pegol plus methotrexate-treated patients compared with placebo plus methotrexate treated-patients had improvements in RA signs and symptoms, and inhibition of structural damage.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, DMARDs & Immunosuppressives, Drug Updates Tagged With: adalimumab, Biologics, Certolizumab Pegol, combination therapy, ixekizumab, Methotrexate, Psoriatic Arthritis, Rheumatoid Arthritis (RA)

You Might Also Like:
  • Certolizumab Pegol Combination Therapy Better than Methotrexate Monotherapy in DMARD-Naive Patients with RA
  • Certolizumab Pegol Effective for Treating Rheumatoid Arthritis
  • Clinical Trial of Ixekizumab for Psoriatic Arthritis Shows Positive Results
  • Ixekizumab Eases Psoriatic Arthritis when TNF Inhibitor Fails

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)